{
 "drug": "Lasmiditan Succinate Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "11/03/2025",
 "dayN": 295,
 "cat": "Neurology",
 "companies": [
  "Eli Lilly and Co."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4491-08",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4491",
     "0002-4312"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-08)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4312-08",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4312",
     "0002-4491"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-08)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4312-62",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4312",
     "0002-4491"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-62)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4312-61",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4312",
     "0002-4491"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-61)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4491-61",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4491",
     "0002-4312"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-61)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0002-4491-62",
   "generic_name": "Lasmiditan Succinate Tablet",
   "contact_info": "800-545-5979",
   "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.",
   "openfda": {
    "application_number": [
     "NDA211280"
    ],
    "brand_name": [
     "REYVOW"
    ],
    "generic_name": [
     "LASMIDITAN"
    ],
    "manufacturer_name": [
     "Eli Lilly and Company"
    ],
    "product_ndc": [
     "0002-4491",
     "0002-4312"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LASMIDITAN"
    ],
    "rxcui": [
     "2256937",
     "2256943",
     "2256945",
     "2256947"
    ],
    "spl_id": [
     "29f467c6-0365-4831-b4ce-9a0eefaf5896"
    ],
    "spl_set_id": [
     "aea3358c-ff41-4490-9e6d-c7bf7b3de13f"
    ],
    "package_ndc": [
     "0002-4312-08",
     "0002-4312-61",
     "0002-4312-62",
     "0002-4491-08",
     "0002-4491-61",
     "0002-4491-62"
    ],
    "unii": [
     "760I9WM792"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Neurology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-62)",
   "company_name": "Eli Lilly and Co.",
   "status": "To Be Discontinued"
  }
 ]
}